探讨益气活血通脉汤治疗在冠心病心绞痛治疗中的效果

目的:分析益气活血通脉汤治疗冠心病心绞痛的临床疗效.方法:采用随机数字表法选择本院2019年1月—2019年10月期间收治的心绞痛型冠心病患者390例,将其分为对照组(n=195)及观察组(n=195).对照组采取基础西药治疗,观察组在对照组的基础上采取益气活血通脉汤治疗,比较两组患者的中医证候积分、血脂指标.结果:观察组与对照组的中医证候积分、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平在治疗后均低于治疗前,高密度脂蛋白胆固醇(HDL-C)高于治疗前,且观察组中医证候积分、TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05).结论:给予冠心病心绞痛患者益气活血通脉汤治疗效果较好,可以改善患者的中医证候,调节血脂水平.     

芪参益气滴丸联合西药对冠心病心绞痛气虚血瘀证患者疗效的影响

目的 通过给予冠心病心绞痛气虚血瘀证患者芪参益气滴丸及西药治疗,探讨其疗效及对中医症状的影响.方法 将59例冠心病心绞痛气虚血瘀证患者随机分为西药组(29例)和西药+中药组(30例).西药治疗:参照美国心脏病学院/美国心脏学会/美国医师学院联合议定的冠心病心绞痛诊断及治疗指南;中药治疗:给予芪参益气滴丸0.5g,tid,治疗60d.观察治疗前后心绞痛疗效、硝酸甘油停减率及中医症状评分变化.结果 治疗后,西药+中药组心绞痛总有效率及硝酸甘油停减率高于西药组,但2组比较无统计学意义(P＞0.05);治疗后,2组胸痛、胸闷症状明显改善,2组与治疗前比较有显著差异性(P＜0.01);西药组气短、乏力、心悸、自汗、面色少华症状无明显改善,与治疗前比较无差异性(P＞0.05).西药+中药组气短、乏力、心悸、自汗、面色少华症状明显改善,与治疗前比较有显著差异性(P＜0.01),西药+中药组中医症状的改善优于西药组,且有显著差异性(P＜0.01).结论 联合应用芪参益气滴丸及西药能有效地改善冠心病心绞痛气虚血瘀证患者的疗效及中医症状,值得临床推广.     

复方血栓通胶囊对稳定型心绞痛NTpro-BNP的影响

目的观察复方血栓通胶囊对冠心病稳定型心绞痛(气虚血瘀型)的临床疗效。方法将80例冠心病稳定型心绞痛患者随机分为治疗组40例和对照组40例,在常规西药治疗的基础上,治疗组给予复方血栓通胶囊口服,疗程为4周。观察治疗前后两组患者的心绞痛发作情况、中医症候以及血Hs-CRP、Hs-TNT和NTpro-BNP的变化。结果在心绞痛发作次数和持续时间的改善方面,治疗组明显优于对照组(P<0.05);在总体证候疗效比较上,治疗组与优于对照组(P<0.05);在NTpro-BNP等各项疗效性指标比较上,治疗组明显优于对照组(P<0.05)。结论复方血栓通胶囊对冠心病稳定型心绞痛疗效确切。     

心可宁胶囊治疗冠心病60例疗效观察

目的 观察心可宁胶囊治疗冠心病的疗效.方法 120例冠心病心绞痛随机分为治疗组和对照组各60例.在常规治疗基础上,治疗组加服心可宁胶囊,对照组加服复方丹参片.两组均以4周为1个疗程.结果 治疗组在中医综合证候疗效、心绞痛和心电图改善方面均优于对照组（均P＜0.05）.结论 心可宁胶囊在改善中医综合证候、心绞痛、心电图方面有满意的疗效.     

舒心饮治疗冠心病心绞痛的随机双盲多中心临床研究

目的:评价中药舒心饮治疗冠心病心绞痛的临床疗效及安全性。方法:采用随机双盲多中心的方法,将133例冠心病心绞痛患者分为治疗组与对照组,分别给予舒心饮、生脉饮治疗4wk,观察患者心绞痛发作情况、中医证候、心电图等指标。结果:治疗组心绞痛的总有效率为90.91%,明显优于对照组的74.63%(P<0.01);治疗后2组患者胸闷、心悸、气短等证候均获得改善,治疗组对胸闷的改善尤为明显(P<0.05);2组患者心电图ST-T的变化均改善;2组间不良反应发生率无显著性差异(P>0.05)。结论:舒心饮治疗冠心病心绞痛安全、有效。     

心脑通胶囊治疗冠心病临床分析

目的观察心脑通胶囊治疗冠心病的临床疗效。方法将患者60例均分为对照与实验组，两组疗程均为1个月。观察心绞痛、中医综合证候、心电图及血液流变学的变化。结果结果两组均能改善心绞痛症状以及降低血脂，但心脑通胶囊组改善中医综合证候疗效显著（P〈0．05）。结论心脑通胶囊是治疗冠心病、心绞痛的有效中成药。     

血府逐瘀汤治疗心绞痛30例临床观察

目的 观察血府逐瘀汤治疗气滞血瘀型心绞痛的临床疗效.方法 将60例气滞血瘀型心绞痛患者完全随机分成观察组(30例)和对照组(30例).对照组给予西药常规治疗;治疗组在对照组治疗的基础之上给予加减血府逐瘀汤治疗,3次/d;观察心绞痛发作次数,中医证候、静息心电图变化及硝酸甘油停减率.结果 观察组心绞痛发作情况总有效率为96.67% ,对照组为76.67%(P<0.05),观察组的心绞痛发作次数、中医证候、静息心电图及硝酸甘油停减率均有明显的改善(P<0.05).结论 加减血府逐瘀汤治疗气滞血瘀型心绞痛有较好疗效.     

中西药联合治疗冠心病心绞痛临床观察

目的:探讨中药冠心丹参滴丸联合西药单硝酸异山梨酯片(欣康分散片)治疗冠心病心绞痛的疗效.方法:38例在我院确诊为冠心病心绞痛(气滞血瘀证)患者,口服冠心丹参滴丸10粒/次,一日三次,和欣康分散片20mg,每日2次;对照组36例,给予欣康分散片20mg,每日2次;8周后对心绞痛、心电图.临床症状及安全性指标进行评估用药前后.结果:心绞痛总有效率治疗组为93.1%,对照组为75.0%(P<0.05);心电图总有效率为74.13%,对照组为47.22%(P<0.05),临床症状中医症候总有效率治疗组为93.1%,对照组为75.0%(P<0.05).结论:中药冠心丹参滴丸能有效地防治冠心病心绞痛发作,联合西药单硝酸异山梨酯片(欣康分散片)能显著提高对冠心病心绞痛的疗效.     

单硝酸异山梨酯片联合定痛救心胶囊治疗冠脉介入术后再发稳定型心绞痛的临床疗效

目的观察单硝酸异山梨酯片联合定痛救心胶囊对冠脉介入术(PCI)后再发稳定型心绞痛的临床疗效和安全性。方法将48例PCI后再发稳定型心绞痛患者随机分为治疗组(24例)和对照组(24例)。对照组口服单硝酸异山梨酯片20mg/次,3次/d;治疗组口服定痛救心胶囊6粒/次,3次/d,单硝酸异山梨酯片的用法和用量同对照组,两组患者均持续治疗8周。治疗结束后,观察两组患者临床疗效、心电图变化、中医证候疗效。结果治疗后治疗组临床疗效、心电图变化、中医证候疗效与对照组比较差异均有统计学意义(P<0.05)。结论单硝酸异山梨酯片联合定痛救心胶囊能有效地改善PCI术后再发稳定型心绞痛患者的疗效,且无不良反应,值得临床推广。     

参芪合剂治疗冠心病心绞痛气虚血瘀证的临床研究

目的探讨参芪合剂治疗冠心病慢性稳定型心绞痛(气虚血瘀证型)的有效性和安全性。方法选取2013年4月~2014年7月本院收治的60例冠心病心绞痛(气虚血瘀证型)患者作为研究对象,随机分为试验组和对照组,各30例。试验组给予参芪合剂,对照组给予养心氏片。比较两组的心绞痛疗效、中医证候疗效、硝酸甘油停减率、心电图疗效和生活质量评分。结果两组的心绞痛和中医证候疗效、硝酸甘油停减率、心电图疗效比较,差异无统计学意义(P>0.05)。两组治疗后的PL、AF、TS、DP评分显著高于治疗前,差异有统计学意义(P<0.05)。试验组治疗后的TS、DP评分显著高于对照组,差异有统计学意义(P<0.05)。结论参芪合剂是治疗冠心病慢性稳定型心绞痛(气虚血瘀证)安全、有效的制剂。     

Lithium and the nephrotic syndrome

The authors report the occurrence of the nephrotic syndrome in association with the use of lithium carbonate in a 41-year-old man, review other reports of this adverse effect, and discuss implications for the clinician.     

Psoriasis and the metabolic syndrome

Psoriasis is a chronic immune-inflammatory-mediated disease that can predispose patients to other inflammatory conditions. For example, individuals with psoriasis are at increased risk for insulin resistance, obesity, dyslipidemia, and hypertension--components that characterize the metabolic syndrome. The metabolic syndrome is an important driver of adverse cardiovascular outcomes. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), and other factors that are overproduced in patients with psoriasis likely contribute to the increased risk for development of metabolic syndrome. This article reviews the association of psoriasis with metabolic syndrome, as well as the impact of biologic agents that are currently used to treat psoriasis (ie, TNF antagonists) on risk factors for metabolic syndrome.     

Neoplasia and the neuroleptic malignant syndrome

The association of neuroleptic malignant syndrome with neoplasia has not been previously reported. We report the case of a 64-year-old female patient who developed the classical picture of neuroleptic malignant syndrome in relation to a uterine leiomyosarcoma. This raises the question as to whether a biological predisposition exists in patients who develop neuroleptic malignant syndrome.     

Hydrogen sulfide and the metabolic syndrome

The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H(2)S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H(2)S and its synthesizing enzyme, cystathionine γ-lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H(2)S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H(2)S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.     

Hydrogen sulfide and the metabolic syndrome

The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H₂S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H₂S and its synthesizing enzyme, cystathionine γ-lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H₂S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H₂S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.